Behçet Disease
19
3
5
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
5.3%
1 terminated out of 19 trials
83.3%
-3.2% vs benchmark
16%
3 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (19)
Deployment o the Multidisciplinary Prospective Cohort Imminent
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
Dusquetide for the Treatment of Behcet's Disease
Understanding the Role of Oral Microbiota in Behçet's Disease (BEHCETBIOT)
Thrombophilia and Thrombosis in Behçet's Disease
How Sirtuin Levels Change During Behçet Disease
The Effect of Music on Sleep Quality in Behçet's Patients
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
IMPACT_BD (IMProving AdherenCe to Treatment in Behçet's Disease)
Interferon α2a Versus Cyclosporine for Refractory Behçet's Disease Uveitis
Plasma Soluble Urokinase Plasminogen Activator Receptor and Behçet's Disease .
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
Erectile Dysfunction in Patients With Non Ocular Behçet's Disease
Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease
Biomarkers of Common Eye Diseases
Inactivity Behavior and Exercise Bariers in Patients With Behçet Disease
Behçet's Disease Overall Damage Index